CurrentPremera BluecrossPolicy 7.01.564

Pulsed Radiofrequency for the Treatment of Chronic Pain

Defines Premera Bluecross medical policy stance on pulsed radiofrequency (PRF) for treatment of various chronic pain syndromes, listing specific indications considered investigational and providing coding, evidence review, guidelines, and history.

Policy Summary

PayerPremera Bluecross

PolicyPulsed Radiofrequency for the Treatment of Chronic Pain

Policy CodePolicy 7.01.564

Change TypeClarifications and additions to investigational indications

Effective DateDec 6, 2018

Next Review Date

Key ActionPRF is considered investigational for the listed chronic pain syndromes; providers should be aware that these services are not supported by sufficient evidence and coverage will follow the investigational determination.

SourceLink

POLICY UPDATE CHANGES

Added to the list of chronic pain syndromes for which pulsed radiofrequency is considered investigational (annual review approved March 10, 2026).

Added anterior cutaneous nerve entrapment syndrome, carpal tunnel syndrome, and frozen shoulder (adhesive capsulitis) to the investigational list (approved September 23, 2024).

Added auriculotemporal neuralgia, genitofemoral neuralgia, and postoperative abdominal wall pain to the investigational list (approved August 12, 2025).

~60Listed Investigational Indications

1Unlisted CPT code referenced

No NCDMedicare National Coverage Determination

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Coverage Summary

Scope overview: This policy defines Premera Blue Cross's stance on Pulsed radiofrequency (PRF) for treatment of various chronic pain syndromes and lists specific indications considered investigational. The policy stance is that PRF is investigational / not covered for the listed chronic pain conditions and providers should document investigational status and use CPT 64999 where appropriate.

Definition and evidence summary: PRF is a non- or minimally neurodestructive technique applying short bursts of radiofrequency energy while maintaining tissue temperatures below neurodestructive thresholds (<42°C). Overall evidence quality is insufficient to determine effects on net health outcomes — controlled data are limited and inconsistent, and Hayes Health Technology Assessments from 2021–2025 report low/very low quality evidence and insufficient support for PRF across several specific indications.

Key Policy Facts

Policy number7.01.564

Effective date2018-12-06

Last review2026-04-01

Next review

StatusCURRENT

Confidence0.9

Investigational / Not Medically Necessary Criteria

Coding

Unlisted procedure codeCPT

64999

Unlisted procedure, nervous system

Provider Actions & Documentation

Documentation Required

Coverage policy requires documentation of investigational status

PRF is considered investigational for the listed chronic pain syndromes; providers should be aware that these services are not supported by sufficient evidence and coverage will follow the investigational determination.

Affected code(s): 64999
Investigational determination may lead to noncoverage/denial

Background, Evidence, and Definitions

Background: Pulsed radiofrequency delivers short intermittent bursts of energy (typically twice per second) with quiet phases that allow electrode cooling so temperatures remain below the neurodestructive threshold (~<42°C). By permitting higher voltage outputs and stronger electrical fields without reaching ablative temperatures, PRF is theorized to modulate ion channels, neurotransmitters, postsynaptic receptors, synaptic function, and immune markers.

Evidence limitations: PRF has been used for many peripheral neuropathies, arthrogenic pain, trigger points, and radiculopathy, but despite anecdotal and observational reports suggesting clinical benefit, there is a lack of high-quality randomized controlled trials and long-term comparative data to establish efficacy and durability.

Evidence summary — quality: The body of evidence includes a small number of RCTs, nonrandomized controlled trials, prospective uncontrolled trials, retrospective studies, case series, and case reports. Many uncontrolled studies report efficacy, but controlled clinical data are limited with inconsistent findings; overall the evidence is judged insufficient to determine effects on health outcomes.

Hayes HTA findings: Multiple Hayes assessments (2021–2025) report low or very low quality evidence and insufficient support for PRF in several indications, including postherpetic neuralgia, chronic cervical spinal pain, sacroiliac-joint low back pain, chronic shoulder pain, lumbosacral radicular pain, and pudendal neuralgia.

Term	Definition
Pulsed radiofrequency (PRF)	A non- or minimally neurodestructive technique applying short bursts of radiofrequency energy to nervous tissue, maintaining temperatures below neurodestructive thresholds (<42°C).

Revision History

2026-04-01clarified (non-material)Latest

Annual Review — References added; specific conditions appended to investigational list (Approved March 10, 2026).

2025-09-01added (non-material)

Annual Review — Added auriculotemporal neuralgia, genitofemoral neuralgia, and postoperative abdominal wall pain to the investigational list (Approved August 12, 2025). Title changed from 'Pulsed Radiofrequency' to 'Pulsed Radiofrequency for the Treatment of Chronic Pain.'

2024-10-01